Teacher Retirement System of Texas Cuts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Teacher Retirement System of Texas decreased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 8.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,382 shares of the biopharmaceutical company’s stock after selling 2,395 shares during the period. Teacher Retirement System of Texas’ holdings in Ocular Therapeutix were worth $186,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Ocular Therapeutix in the fourth quarter worth about $28,000. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix in the fourth quarter worth about $43,000. GAMMA Investing LLC grew its position in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 8,112 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 8,446 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in Ocular Therapeutix in the first quarter worth about $79,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

OCUL has been the subject of several analyst reports. William Blair initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an “outperform” rating for the company. Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $17.33.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $11.33 on Monday. The company has a 50 day moving average price of $8.80 and a 200-day moving average price of $8.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. Ocular Therapeutix, Inc. has a fifty-two week low of $5.79 and a fifty-two week high of $11.78. The company has a market capitalization of $1.80 billion, a PE ratio of -9.85 and a beta of 1.43.

Insider Activity at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director owned 172,704 shares of the company’s stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider directly owned 3,499,099 shares of the company’s stock, valued at $25,123,530.82. This represents a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,079 shares of company stock valued at $208,739 in the last ninety days. Insiders own 2.30% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.